lactam bridge raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
On June 22, 1941, Germany broke the Molotov–Ribbentrop Pact with Operation Barbarossa, the invasion of the Soviet Union through the territories that the two countries had previously divided. Stalin switched his cooperation from Hitler to Winston Churchill. Britain and the Soviets signed a formal alliance, but the US did not join until after the Attack on Pearl Harbor on December 7, 1941. Immediately, there was disagreement between Britain's ally Poland and the Soviet Union. The British and Poles strongly suspected that when Stalin was cooperating with Hitler, he ordered the execution of about 22,000 Polish officer POWs, at what was later to become known as the Katyn massacre. Still, the Soviets and the Western Allies were forced to cooperate, despite their tensions. The US shipped vast quantities of Lend-Lease material to the Soviets. Britain agreed a broader military and political alliance in 1942. During the war, both sides disagreed on military strategy, especially the question of the opening of a second front against Germany in Western Europe. As early as July 1941, Stalin asked Britain to invade northern France, but Britain was in no position to carry out such a request. Stalin had also requested that the Western Allies open a second front from the early months of the war—which finally occurred on D-Day, June 6, 1944. The US and Britain initially indicated that they would open the second front in 1942, and then in 1943, but it was postponed both times.
Iron has four stable isotopes: 54Fe (5.845% of natural iron), 56Fe (91.754%), 57Fe (2.119%) and 58Fe (0.282%). Twenty-four artificial isotopes have also been created. Of these stable isotopes, only 57Fe has a nuclear spin (−1⁄2). The nuclide 54Fe theoretically can undergo double electron capture to 54Cr, but the process has never been observed and only a lower limit on the half-life of 4.4×1020 years has been established. 60Fe is an extinct radionuclide of long half-life (2.6 million years). It is not found on Earth, but its ultimate decay product is its granddaughter, the stable nuclide 60Ni. Much of the past work on isotopic composition of iron has focused on the nucleosynthesis of 60Fe through studies of meteorites and ore formation. In the last decade, advances in mass spectrometry have allowed the detection and quantification of minute, naturally occurring variations in the ratios of the stable isotopes of iron. Much of this work is driven by the Earth and planetary science communities, although applications to biological and industrial systems are emerging. In phases of the meteorites Semarkona and Chervony Kut, a correlation between the concentration of 60Ni, the granddaughter of 60Fe, and the abundance of the stable iron isotopes provided evidence for the existence of 60Fe at the time of formation of the Solar System. Possibly the energy released by the decay of 60Fe, along with that released by 26Al, contributed to the remelting and differentiation of asteroids after their formation 4.6 billion years ago.
== Further reading == Rappoport, n.; Paik, P.; Oskotsky, B.; Tor, R.; Ziv, E.; Zaitlen, N.; Butte, A. (2018). "Comparing Ethnicity-Specific Reference Intervals for Clinical Laboratory Tests from EHR Data". The Journal of Applied Laboratory Medicine. 3 (3): 366–377. bioRxiv 10.1101/213892. doi:10.1373/jalm.2018.026492. PMC 8404742. PMID 33636914.
Sources: en.wikipedia.org
homoserine + NAD(P)+ Homoserine represents another branch in the aspartate pathway, as it can progress down one of two pathways to eventually become one of two amino acids: threonine or methionine. This aspartate pathway is present in plants and bacteria, allowing them to synthesize lysine, methionine, and threonine. This pathway is not present in humans or other animals, however. The lack of this pathway means that humans need to take in these amino acids through their diet, which is why they are called essential amino acids.
2024 Greater Manchester mayoral election: Labour's Andy Burnham secures a third term as Mayor of Greater Manchester with almost two-thirds of the votes cast. The SDLP announces that it will change the way it makes "civil leadership" appointments following the resignation from the party of two Derry City and Strabane District Council councillors over the appointment of Lilian Seenoi-Barr as the authority's next mayor. 5 May – With all votes counted, the results from the local elections in England are: Labour 1,158 (+186), Liberal Democrat 522 (+104), Conservative 515 (−474), Independents and others 228 (+93), Green 181 (+74), Residents' Association 48 (+11), Workers Party of Britain 4 (+4), Reform UK 2 (+2). 6 May – Argentina's president, Javier Milei, tells the BBC he accepts the Falkland Islands are currently "in the hands of the UK", but says his country will get them back through diplomatic channels. John Swinney is confirmed as Leader of the Scottish National Party after being unopposed in the leadership election, and begins his second tenure in the post. 7 May – John Swinney wins the backing of the Scottish Parliament to become Scotland's seventh First Minister, and will be sworn into office the next day. The Green Party's Siân Berry, who was re-elected in the 2024 London Assembly election, is criticised for resigning three days later to hand her seat to Zoë Garbett, who lost in the same election with 5.8% of the vote.
According to Kate Brown, the plutonium production plants at Hanford and Mayak in Russia, over a period of four decades, "both released more than 200 million curies of radioactive isotopes into the surrounding environment—twice the amount expelled in the Chernobyl disaster in each instance". Most of this radioactive contamination over the years were part of normal operations, but unforeseen accidents did occur and plant management kept this secret, as the pollution continued unabated. In 2004, a safe was discovered during excavations of a burial trench at the Hanford nuclear site. Inside the safe were various items, including a large glass bottle containing a whitish slurry which was subsequently identified as the oldest sample of weapons-grade plutonium known to exist. Isotope analysis by Pacific Northwest National Laboratory indicated that the plutonium in the bottle was manufactured in the X-10 Graphite Reactor at Oak Ridge during 1944.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.